Myriad Genetics (MYGN) 10-K2003 FY Annual report

Filed: 22 Sep 03, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: accelerated, accomplish, adequacy, ADME, antiviral, arrive, Australia, bad, breach, budding, charter, civil, clearinghouse, Committee, content, conventional, criminal, deadline, Diego, discourage, disproportionate, dominant, doubtful, electronic, electronically, elucidate, embedded, enroll, enrolled, enrollment, enterprise, enzyme, Europe, exhausted, filer, fill, framework, gap, HHS, HIPAA, hit, hormone, hostile, inactive, inconclusive, inconvenient, insight, interim, intervention, invoiced, IV, journalCell, length, loan, margin, metastatic, methodology, mild, mimetic, moderate, Morgan, negative, nonrenewal, observing, oral, parent, passed, pending, peptide, pharmacokinetic, poison, Portability, prevalent, privacy, proportional, prove, proximity, purpose, recall, recovery, recurrence, redone, refusal, remedial, remediate, remote, repeat, repeated, residual, revised, RNA, San, satisfactorily, Simplification, simplifying, specialty, staggered, Stanley, sterile, stringent, suspension, team, textual, toxicology, transmission, twelve, underwritten, undetected, variable, version, viability, violation, waiting, Wakara, watchful, web, written, Zealand

Removed: achieved, Acqua, agent, Agricultural, AGT, alliance, Annex, announced, arising, biochemistry, biology, Biotech, blood, built, capture, central, cGMP, chemoprevention, chronic, Clinton, codified, commonly, complement, concerted, detected, diet, dietary, disclosed, disposition, DNA, dramatically, easily, easy, established, exploring, extend, extracted, extremely, fund, fundamental, generate, genetically, granting, grew, highest, hypertensive, increasing, inexpensive, inflammatory, Institute, Intermountain, introducing, locate, maintaining, mammalian, manipulated, Modernization, Monsanto, mortality, mutant, nonexclusive, North, obstructive, offer, optimizing, pain, personalized, potentially, predisposed, president, produced, PSA, pulmonary, receipt, reduction, reimbursed, released, retiring, rheumatoid, saving, selecting, sequence, showed, sleep, strain, stroke, subsidiary, unknown, unproductive, Valley, variant, vast, Wellington, withdrawal, yeast

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

MYGN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Myriad Genetics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Annual Report for the year ended June 30, 2003 on Form 10-K of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: September 17, 2003		Date: September 17, 2003

/s/ PETER D. MELDRUM		/s/ JAY M. MOYES
Peter D. Meldrum		Jay M. Moyes
President and Chief Executive Officer		Vice President of Finance and Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.